Efferon

Austrian Startup Efferon Expands Blood-Purification Technology After Securing Paediatric Approval in Europe

by

Austrian startup Efferon, founded in 2016, creates blood‑purification cartridges that remove bacterial toxins and inflammatory mediators to treat sepsis. After receiving European CE MDR approval for its adult device in 2024 and paediatric certification in 2026, the devices have been used in over 25,000 treatments in 44 countries, generating more than €1 million in revenue. Efferon is now pursuing US regulatory pathways, expanding into China, and developing an outpatient solution for post‑sepsis and chronic inflammation.

Austrian Biotech Efferon Secures €2.5M Seed Funding to Expand Sepsis Treatment Manufacturing Across Europe

by

Efferon, a biotech company developing hemoadsorption devices for treating sepsis and septic shock, has secured €2.5 million in seed funding led by private investors from the DACH region. The company will use funds to build a new EU production facility and expand manufacturing capacity. Efferon’s products include Efferon LPS for general use and Efferon NEO for pediatric patients, with the latter recently receiving CE MDR certification. The technology has been used in over 25,000 treatments across 40+ countries.